about
Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humansA phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group InvestigationA phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatinAdaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma.Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer.A Retinol Isotope Dilution Equation Predicts Both Group and Individual Total Body Vitamin A Stores in Adults Based on Data from an Early Postdosing Blood Sample.Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK).Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug developmentPharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients.Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study.An LC/MS/MS method for stable isotope dilution studies of β-carotene bioavailability, bioconversion, and vitamin A status in humans.A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours.Thiothymidine combined with UVA as a potential novel therapy for bladder cancer.Chemotherapy individualization.Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy.Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancer.High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers.Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo.Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo.Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - a study of the United Kingdom Children's Cancer Study Group.Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factorPhase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations.Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma.Estimation of glomerular filtration rate in paediatric cancer patients using 51CR-EDTA population pharmacokineticsDevelopment of a physiologically based pharmacokinetic model of actinomycin D in children with cancer.Estimation of renal function and its potential impact on carboplatin dosing in children with cancerPhase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancerPhase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.Plasma Retinol Kinetics and β-Carotene Bioefficacy Are Quantified by Model-Based Compartmental Analysis in Healthy Young Adults with Low Vitamin A StoresPharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial.Towards a Model-Based Dose Recommendation for Doxorubicin in Children.Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedulesPharmacogenetics of genes across the doxorubicin pathway.
P50
Q24304272-E3B14234-7B44-4FED-BFC0-C4B070EF9CD0Q28345464-79C62502-4620-42DD-B197-52C8ED77F55AQ28362947-73EC8CF7-8D75-4F32-91D4-0374E44C9634Q30532640-94D0C448-FCC0-4FC8-9549-9EECE3E075ECQ30584978-3DF6A1BE-C19F-4FD1-A0E2-8AC268FE3B7AQ31121031-8567BD2B-53CE-4535-B42B-9AC589C61FA6Q33330713-9653425C-6D11-4BAB-BBCC-3F325B7642B6Q33366086-20373E77-0F42-4A8C-B53E-B55989E5EB39Q33377236-4973D74B-DB02-4981-848F-629E3B482169Q33385937-08DCA182-8915-471F-84DE-2B1F8D271349Q33403458-DF4CD7DB-A276-475F-8F3F-7A008B321544Q33418532-1A71B375-4112-44AE-9580-CACC243D364EQ33459601-482E8737-7503-4C4F-B208-C2B5DDC19719Q33497955-D64A5A74-51A8-4484-B4F5-FF638EA9AB13Q33729396-0100E16F-C69D-4432-AF87-CAE2801D7126Q33747406-19E75562-53DF-49D1-AC8A-8D01C196E6C9Q34627989-145FB862-4917-44E4-A368-CA05A9055417Q35034773-7039B4B0-5148-4319-914F-73874AC649BFQ35188391-B3123F12-23EF-4892-A462-778B9CC4ECF3Q35799917-74D2185D-3FF5-4F5D-B4D1-55052FD31060Q35827602-5761BE8F-45ED-438F-989F-7898F766D921Q35895739-09E3063F-59CC-487C-AFB7-3C99D681BC14Q36532522-72814C45-87F9-499C-B7BF-FB1ABA6EB6F5Q36533306-D2D92CC2-32A3-4F76-B805-64930A16C44AQ36609453-D82CD63B-F0CB-49B8-8008-04D4717500FDQ36609788-041CF0FC-27E8-43A3-802C-06BCA8CEFFC3Q36609993-90738372-A3D4-44E3-B88E-EB16C1EB0433Q36611873-ABF5388F-368B-4059-90D3-47C5B03A4F81Q36616482-88199080-66F5-4BCD-A98B-1C9C04B63324Q36652629-5A6FD43D-6449-4821-8015-09AB2DE24B56Q36673641-7B0A9596-F59B-4539-9A60-560469092401Q36806598-4C899B32-DFC4-47F0-9486-637E30385177Q36882682-F78BE147-1518-4F70-9A5A-5AC7084BD51CQ36941966-EBDF4313-8B61-4663-AAE8-EF2A760B9F9CQ37121130-D566F9D2-F0D4-47AB-989E-C4AB5AEAEBB1Q37286705-21BE6BC7-1417-4944-8B2B-6003E76D6A75Q37421271-FD5A7400-DF11-4597-B197-229650D0EF75Q37650674-3DFF56E7-0E71-4D98-815A-97153E3812CBQ37711694-9BEA8350-EEB1-45EA-858F-B5E7B3989824Q37932556-A91B6585-8E07-4AD3-A4F8-5930B7962602
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Alan V. Boddy
@ast
Alan V. Boddy
@en
Alan V. Boddy
@es
Alan V. Boddy
@nl
Alan V. Boddy
@sl
type
label
Alan V. Boddy
@ast
Alan V. Boddy
@en
Alan V. Boddy
@es
Alan V. Boddy
@nl
Alan V. Boddy
@sl
prefLabel
Alan V. Boddy
@ast
Alan V. Boddy
@en
Alan V. Boddy
@es
Alan V. Boddy
@nl
Alan V. Boddy
@sl
P108
P106
P1153
7006184991
P21
P31
P496
0000-0002-8920-9286